Streetbeat News

Analyst Ratings

NUVL

JP Morgan analyst Anupam Rama has maintained an Overweight rating on Nuvalent (NASDAQ:NUVL) and increased the price target from $100 to $125.

Portfolio Pulse from Benzinga Newsdesk

October 04, 2024 | 6:25 pm

DTM

JP Morgan analyst Jeremy Tonet maintains a Neutral rating on DT Midstream (NYSE:DTM) but raises the price target from $78 to $83.

Portfolio Pulse from Benzinga Newsdesk

October 04, 2024 | 6:22 pm

F

GM

STLA

RBC Capital analyst Tom Narayan downgraded Stellantis (NYSE:STLA) due to inventory issues and potential downward pricing pressure. The price forecast for Stellantis' Paris-listed stock was lowered, and EBIT margin estimates were revised down. Despite short-term challenges, the analyst remains optimistic about Stellantis' long-term potential.

Portfolio Pulse from Nabaparna Bhattacharya

October 04, 2024 | 6:19 pm

ANF

JP Morgan analyst Matthew Boss maintains an Overweight rating on Abercrombie & Fitch and raises the price target from $194 to $195.

Portfolio Pulse from Benzinga Newsdesk

October 04, 2024 | 6:19 pm

WPM

Jefferies analyst Chris LaFemina has maintained a Buy rating on Wheaton Precious Metals (NYSE:WPM) and increased the price target from $67 to $77.

Portfolio Pulse from Benzinga Newsdesk

October 04, 2024 | 6:16 pm

TFPM

Jefferies analyst Chris LaFemina maintains a Buy rating on Triple Flag Precious (NYSE:TFPM) and raises the price target from $20 to $22.

Portfolio Pulse from Benzinga Newsdesk

October 04, 2024 | 6:12 pm

AXSM

Axsome Therapeutics (NASDAQ:AXSM) has received mixed analyst ratings over the past three months, with a majority being bullish or somewhat bullish. The average 12-month price target has slightly increased to $128.05. Despite impressive revenue growth, the company faces challenges with profitability and asset utilization.

Portfolio Pulse from Benzinga Insights

October 04, 2024 | 6:08 pm

CNMD

Conmed (NYSE:CNMD) has received mixed ratings from analysts, with a majority being bullish. The average 12-month price target is $87.83, a decline from previous estimates. Analysts have adjusted their ratings and price targets in response to market conditions. Conmed's financial performance shows strong net margins and ROE, but its revenue growth lags behind industry peers.

Portfolio Pulse from Benzinga Insights

October 04, 2024 | 6:05 pm

KMX

Oppenheimer analyst Brian Nagel has reiterated an 'Outperform' rating for CarMax (NYSE:KMX) and maintained a price target of $105.

Portfolio Pulse from Benzinga Newsdesk

October 04, 2024 | 6:05 pm

EXEL

Exelixis (NASDAQ:EXEL) has received varied analyst ratings over the past three months, with a majority being somewhat bullish. The average 12-month price target has increased to $29.22. Exelixis has shown strong financial performance with a 35.61% revenue growth rate, a 35.49% net margin, and a low debt-to-equity ratio of 0.09.

Portfolio Pulse from Benzinga Insights

October 04, 2024 | 6:05 pm